Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

A Critique of the Public Citizen and TB Alliance Reports
Tufts Center for the Study of Drug Development, 11-1-04

The Tufts Center for the Study of Drug Development has published a very well regarded estimate on the costs of drug development - published in a peer reviewed economics journal - from “invention to regulatory marketing approval”: approximately $800 million. Critics of the pharmaceutical industry, particularly the consumer advocate group Public Citizen, have published their own estimates, which are substantially lower than the Tufts figure. These estimates have been cited approvingly in several public critiques of industry, but according to Tufts “these reports have not undergone anonymous peer review, and have not been scrutinized fully for methodological flaws or the propriety of using results from them as comparators from our work.”

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000